Effects of β-endorphin on brain serotonin metabolism

Human β-endorphin (15 μg) administered intracisternally increased concentrations of serotonin (5HT) and its metabolite, 5-hydroxyindoleacetic. acid (5-HIAA), in brain stem and hypothalamus and decreased 5-HIAA concentrations in hippocampus. These data are compatible with the hypothesis that β-endorphin increases 5HT turnover in brain stem and hypothalamus and decreases 5HT turnover in hippocampus. β-endorphin increased in brain stem and hypothalamus and decreased in hippocampus the rate of pargyline-induced decline of 5-HIAA. β-endorphin decreased the rate of pargyline-induced accumulation of 5HT in all these brain regions. The probenecid-induced accumulation of 5-HIAA in brain stem was decreased by β-endorphin. These data are compatible with the hypothesis that β-endorphin increases release of 5HT from neurons in brain stem and hypothalamus and decreases release of 5HT from neurons in hippocampus. The data require further a hypothesis that β-endorphin either decreases 5HT reuptake in these three brain regions or increases 5-HIAA egress from brain.     

Low permeation of systemically administered human ß-endorphin into rabbit brain measured by radioimmunoassays differentiating human and rabbit ß-endorphin

Two antisera against human β-endorphin were generated in rabbits. They were found to differ largely in their specificities. One antiserum did not recognize rabbit β-endorphin. This antiserum was used to investigate the permeation of human β-endorphin into rabbit brain and cerebrospinal fluid after systemic injection of the synthetic peptide (50 μg/kg). Over a period of two hours, a low but significant permeation was found to occur only into the hypothalamus. All other brain areas remained below radioimmunoassay detection limits of 100 fmoles/g. Post-injectional cerebrospinal fluid concentrations of human β-endorphin showed very low values (90 fmoles/ml maximally). A regional distribution of rabbit brain β-endorphin, very similar to other species, was found using the antiserum which detected rabbit β-endorphin.     

Alpha-endorphin, gamma-endorphin and their des-tyrosine fragments in rat pituitary and brain tissue

Enkephalins, endorphins and related peptides were determined in pituitary and brain tissue of rats which were killed by decapitation or microwave irradiation. The tissues were heated in 1M acetic acid prior to homogenization and the levels of the various peptides were measured by means of a combination of HPLC and radioimmunoassays. Enkephalin levels in pituitary and brain of irradiation-killed rats were much higher as compared to those in tissue of rats sacrificed by decapitation. Similar data were obtained with respect to pituitary levels of γ-endorphin, des-Tyr-γ-endorphin and des- Tyr-α-endorphin. However, brain levels of α- and γ-endorphin and their respective des-Tyr-fragments were not different with the two methods of sacrifice used. The concentrations of β-endorphin in the pituitary gland were similar in rats killed by microwave irradiation and decapitation, but irradiation showed higher β-endorphin levels in the brain than decapitation. These results suggest that β-endorphin fragments like α- and γ-endorphin and des-Tyr-α- and des-Tyr-γ-endorphin are endogenous peptides in the rat pituitary gland and the brain.     

Preparation of tritium labeled beta-endorphin suitable for studying brain receptor interactions

The opioid peptide (porcine) β-endorphin has been tritiated using reductive methylation to prepare a derivative containing mainly [³H]dimethyllysine. The tritiated β-endorphin has a specific activity of 9.8 Ci/mmol and is stable for an extended period of time. The labeled peptide binds reversibly to rat brain membrane preparations with a dissociation constant of 0.4 ± 0.1 nM and a receptor content of 23 ± 2 pmol/g brain. Under the conditions used, there is evidence for only one class of receptors. The technique employed for tritium labeling of β-endorphin should also be applicable to various other peptides including α-endorphin, γ-endorphin, and C′-fragment that have been found in brain and pituitary.     

Beta-endorphin induced akinesia in rats: effect of apomorhine and alpha-methyl-p-tyrosine and related modifications of dopamine turnover in the basal ganglia

β-Endorphin (amino acid sequence 61–91 of β-lipotropin) administered intraventricularly at a dose of 13 n moles in rat induced akinesia and loss of corneal reflex. Apomorphine (20 mg/kg) which had been injected subcutaneously 20 minutes after the administration of β-endorphin fully reversed akinesia and elicited characteristic stereotyped behavior. During complete disappearance of akinesia, the corneal reflex was found to be still absent. Apomorphine (5 mg/kg) only partially reversed akinesia. Pretreatment with α-methyl-p-tyrosine (α-MT, 250 mg/kg) potentiated the effect of β-endorphin upon muscle rigidity. In a biochemical study, rats received β-endorphin (15 n moles) 60 minutes before sacrifice. Concentrations of dopamine (DA) and norepinephrine (NE) were not altered in any brain regions. A significant increase in concentrations of 5-hydroxytryptamine was obtained in the midbrain. In a DA and NE turnover study, rats received α-MT (250 mg/kg) 4 hours prior to β-endorphin and were sacrificed 60 minutes later. β-Endorphin partially corrected the decreased concentrations of DA induced by α-MT in the midbrain. A similar tendency toward correction of the decreased DA concentrations was observed in the striatum. The concentrations of NE decreased by α-MT in the midbrain, striatum and hypothalamus were not modified by β-endorphin     

Acetylated and nonacetylated forms of beta-endorphin in rat brain and pituitary

Extracts of rat posterior intermediate pituitary and extracts of brains from normal and hypophysectomized rats were separated by gel filtration chromatography and fractions were analyzed by both a classical β-endorphin radioimmunoassay and by a radioimmunoassay specific for α-N-acetyl β-endorphin. In posterior intermediate pituitary extracts, more than 90 percent of the β-endorphin-sized immunoreactive material was α-N-acetylated. In extracts of brains from normal rats, less than 2 percent of the β-endorphin-sized immunoreactive material corresponded to α-N-acetylβ-endorphin, whereas in brains from hypophysectomized animals, no α-N-acetylβ-endorphin-like material could be detected. Immunofluorescence on normal brain sections, using either affinity purified antibodies to α-N-acetylβ-endorphin or conventional β-endorphin antibodies, showed no α-N-acetylβ-endorphin immunoreactivity in β-endorphin neurons. Only in brain sections which had been acetylated $\text{in}\text{vitro}$ prior to immunostaining could α-N-acetylβ-endorphin-like material be detected in the β-endorphin neurons. These results suggest that—in contrast to the cells in the intermediate lobe of the pituitary—the β-endorphin in brain neurons is not α-N-acetylated and that the small amount of α-N-acetyl β-endorphin which can be found in extracts of brains from normal animals is probably of pituitary origin.     

Radioimmunoassay of brain peptides: Evaluation of a methodology for the assay of β-endorphin and enkephalin

The brain levels of β-endorphin, α-endorphin and enkephalin were measured by radioimmunoassay after different methods of sacrifice. Microwave irradiation proved not to be better than decapitation followed by boiling of the intact tissue, the latter procedure giving values of β-endorphin 10 fold higher than decapitation alone. Concurrently when decapitation was followed by boiling, α-endorphin was no longer detected. Evaluation in brain tissue of several extraction media--phosphate buffered saline, 5% TCA, HCl methanol, and 1N HOAc--showed the last to be the most satisfactory for both β-endorphin and enkephalin. Since β-endorphin was found to be readily hydrolized by brain homogenates with consequent appearance of α-endorphin, these results indicate that disruption of tissue modifies the content of opioid peptides in brain.     

Endorphins and the central inhibition of urinary bladder motility

The involvement of endogenous opioid mechanisms in the central neurogenic control of urinary bladder function has been examined in anesthetized rats. Intracerebroventricular (ICV) microinjection of β-endorphin (0.5–2.0 μg) produced powerful inhibition of rhythmic bladder contractions initiated by central reflex activity. The peptide fragments γ-endorphin and α-endorphin (4–16 μg), formed by the processing of β-endorphin by membrane homogenates of brain, were less active than the parent compound. The inhibitory effects of β-endorphin was reversed by ICV naloxone (1–2 μg) but higher doses were required to reverse γ- or α-endorphin effects. ICV naloxone administered alone increased intravesicular pressure and bladder contraction frequency. These observations support the hypothesis that the endorphins have a physiological role in the central regulation of urinary bladder activity.     

Presence of immunoassayable beta-lipotropin in bovine brain and spinal cord: lack of concordance with ACTH concentrations.

Discrete areas of freshly obtained adult bovine brain were assayed for their content of immunoreactive β-lipotropin (β-LPH), ACTH and β-endorphin. Highest concentrations (pg/100ug protein) of β-LPH were present in hypothalamus (517 ± 81), hippocampus (218 ± 60), central grey rostral mesencephalic level, pons, striatum, and spinal cord (163–258). Lesser concentrations (49–138) were present in other parts of the limbic system, brain stem, cortex and thalamus. Immunoreactive ACTH concentrations were highest in hypothalamus (1702 ± 487) and hippocampus (210 ± 40), with markedly lesser concentrations (5–24) being present in all the other aforementioned areas. Immunoreactive β-endorphin concentrations in hypothalamus were 1990 ± 510, in hippocampus 280 ± 50.     

Influence of β-endorphin on the proliferative and phagocytic activities of peripheral blood cells of men and women from different age groups

It has been found that β-endorphin modulation of lymphocyte proliferative activity in male donors is mainly observed at a relatively young age (in groups aged 20–29 and 30–39 years), it gradually becomes lower with age, and disappears in donors at aged 50–60 years. At the same time, women have a prolonged modulating effect of peptide on proliferation. In women aged 50–59 years, the peptide has a marked promotional effect on spontaneous proliferation at concentrations of 10^?7, 10^?8, and 10^?10 M induced by a suboptimal concentration of phytohemagglutinin (PHA) at 10^?10 M, while in women aged 30–39 years, β-endorphin suppresses PHA-induced proliferative response. In men aged 20–29 years, β-endorphin stimulates the uptake capacity of neutrophils, whereas in those aged 50–59 years, this capacity is suppressed by β-endorphin. In female donors from any age groups, β-endorphin was not found to influence the activity of neurophils.     

beta-Endorphin administration increases hippocampal acetylcholine levels.

The contents of acetylcholine and choline were determined in rat cortex, striatum, and hippocampus following intraventricular injection of β-endorphin or D-Ala²-enkephalinamide, a synthetic enkephalin analog, in doses known to produce analgesia in experimental animals. These opiate polypeptides produced significant increases in acetylcholine levels in the hippocampus, a subcortical structure rich in cholinergic terminals. The acetylcholine content of the hippocampus (but not the cortex or striatum) was significantly elevated 15, 30, and 60 minutes after a single intraventricular injection of β-endorphin (10 μg/brain) or D-Ala²-enkephalinamide (10 μg/brain). Peak alterations in regional acetylcholine concentrations and in analgetic effectiveness both occurred 30 minutes after peptide administration. Choline concentrations were unchanged by any of the experimental treatments. Naloxone hydrochloride (1 mg/kg, subcutaneously) affected neither brain acetylcholine concentrations, nor the response latencies of rats placed on a hot-plate; it did, however, antagonize the changes in these parameters caused by β-endorphin or D-Ala²-enkephalinamide. These data suggest that endorphins may normally regulate the physiologic activity of some cholinergic neurons.     

Effect of beta-endorphin on gastric acid secretion and serum gastrin concentration in humans

The effect of synthetic human β-endorphin on gastric acid secretion was studied in 9 healthy subjects. Neither 2.5 mg or 15 mg β-endorphin had a significant effect on acid secretion or on serum gastrin concentration despite the fact that this dose of opiate caused a significant increase in serum prolactin concentrations. The role of endogenous opiate-like peptides on gastric secretion is discussed.     

Comparison of β-endorphin immunoreactivity in hypothalamic and brainstem nuclei of normotensive and age-matched hypertensive rat strains

The concentration of β-endorphin immunoreactivity was determined in 21 hypothalamic and brainstem nuclei of Sprague-Dawley (SD) and 6 and 14 week Wistar-Kyoto (WKY) and Spontaneously Hypertensive (SH) rats. The concentrations of β-endorphin immunoreactivity were greater in the hypothalamic nuclei than in the brainstem nuclei approximately by a factor of 5. A significant strain-age interaction was observed in the β-endorphin immunoreactivity levels in the anterior hypothalamic area, paragigantocellular reticular nucleus and locus coeruleus of age-matched SH and WKY rats in that immunoreactivity levels fell in the age period studied (6–14 weeks) in WKY rats and rose in SH rats. These biochemical differences are related in time to a growth period during which there are large increases in blood pressure in the SH rat and may thus have a pathogenetic significance.     

Sex Differences in the Content of β-Endorphin and Enkephalin-Like Peptides in the Pituitary of Obese (ob/ob) Mice

Abstract: The β-endorphin content in pituitary extracts of male and female obese (ob/ob) and lean (+/?) mice was determined by radioimmunoassay. The amount of β-endorphin-like material contained in the pituitary of 3-month-old ob/ob male mice is similar to that of lean male mice. In contrast, the pituitary glands of female ob/ob mice have a greater amount of β-endorphin-like material than lean female mice. To determine with greater precision the molecular nature of the polypeptide that accounts for the increase in β-endorphin immunoreactivity, the various molecular forms of β-endorphin immunoreactivity were resolved by Biogel P-30 column chromatography. At least four peaks of immunoreactive material were detected. The first peak elutes in the void volume, and the second and the third peaks appear in the elution volumes of β-lipotropin and β-endorphin, respectively. That the material present in the void volume might be proopiocortin is supported by adrenocorticotropic hormone radioimmunoassay. The increased total β-endorphin immunoreactivity in pituitary glands of ob/ob mice is accounted for mainly by β-endorphin. The β-endorphin content of various brain structures of ob/ob mice is similar to that of lean littermates.     

Conversion of Des-tyrosine-γ-endorphin by brain synaptic membrane associated peptidases: Identification of generated peptide fragments

Des-tyrosine-γ-endorphin, a β-endorphin fragment with neuroleptic-like properties, was digested with a cSPM fraction of rat brain. A profile of metabolites and a time course of conversion were obtained by HPLC analysis of the digests. Quantitative amino acid analysis and a second HPLC fractionation step which was designed to separate and to identify very similar des-tyrosine-γ-endorphin fragments, combined with dansyl end group determination allowed the characterization of β-LPH 65–77, β-LPH 66–77 and β-LPH 62–73 as main conversion products. In the digests the C-terminal leucyl peptides β-LPH 67–77 and β-LPH 68–77 as well as the N-terminal glycyl peptides β-LPH 62–74 and β-LPH 62–76 were minor components. The data indicate the involvement of several types of peptidase activities in the conversion process. It is suggested that these peptidases have a role in mediating in vivo des-tyrosine-γ-endorphin effects. In addition, this study points to the capacity of the brain to gene-rate small peptides with neuroleptic-like properties.     

Biosynthesis of beta-endorphin, beta-lipotropin and the putative ACTH-LPH precursor in the frog pars intermedia.

When frog pars intermedia are incubated for 3 h with radioactive methionine, the predominant labeled peptide is one with an apparent molecular weight of 33, 100. This peptide can be immunoprecipitated with antisera against β-melanotropin (β-MSH), adrenocorticotrophin (ACTH), and β-endorphin and is believed to be the common precursor of ACTH and β-lipotropin (β-LPH). Immunoprecipitation experiments have also demonstrated the presence of labeled β-LPH and β-endorphin. The labeled β-endorphin has been shown to behave identically to sheep β-endorphin on both carboxymethyl-cellulose chromatography and polyacrylamide gel electrophoresis. Frog β-endorphin has methionine as the fifth residue, as do all other β-endorphins that have been sequenced.     

β-endorphin-induced increase in striatal dopamine turnover

Human β-endorphin administered intracisternally in a dose of 15 μg per rat increased striatal concentrations of the dopamine metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) as well as producing catalepsy. These effects were inhibited by naloxone. Pargyline-induced decreases in striatal DOPAC and HVA were greater in endorphin-treated than in saline-treated animals, supporting the concept that β-endorphin increases striatal dopamine turnover. β-endorphin increased the rate of decline in striatal dopamine concentration following synthesis inhibition with α-methyltyrosine, further suggesting that endorphin increases striatal dopamine turnover. β-endorphin and probenecid interacted competitively to decrease the effects of each other to increase striatal HVA. Naloxone prevented the effect of endorphin to decrease the HVA response to probenecid. Thus, probenecid cannot be used to assess the effects of endorphin on striatal dopamine turnover. If β-endorphin acts presynaptically to decrease dopamine release in striatum, the increases in striatal DOPAC and HVA probably represent a compensatory attempt to increase dopamine synthesis. Although turnover of dopamine to its metabolites is increased, dopamine release may be suppressed by β-endorphin.     

Proteolysis of β-endorphin in brain tissue

The processing of β-endorphin by brain enzymes into peptides related to the behaviorally active γ- and α-type endorphins and the sequence of proteolytic events in the conversion process are described. Multiple enzyme activities contribute to the generation of the peptides with neurotropic activity. It is proposed that the processing into γ- and α-type neuropeptides is a post-secretional event. The enzymes involved may have a key role in the nature and levels of neurotropic β-endorphin fragments in the brain.     

Pituitary β-endorphin content during spontaneous food intake and body weight cycles in the dormouse, Glis glis

Pituitary β-endorphin content was measured in dormice during several distinct phases of the infradian body weight cycle. No significant differences in opiate content among groups were found. It appears unlikely that pituitary concentrations of β-endorphin have etiological significance in the development of spontaneous obesity in hibernators.     

Effect of bacitracin on the biodegradation of β-endorphin

β-endorphin was incubated with rat brain homogenate, and the amino acids released were measured by amino acid analysis. Phe, Leu, Tyr, and Lys were liberated in the greatest amount indicating that the cleavage of Leu⁷⁷-Phe⁷⁸ and some Lys-X peptide bonds with endopeptidases followed by the removal of the terminal residues by exopeptidases are the main routes of β-endorphin degradation in the brain. Bacitracin considerably reduced the amino acid release from β-endorphin incubated with rat brain homogenate, and its action is suggested to be due to the inhibition of brain amino- and carboxypeptidases. Bacitracin also potentiated and prolonged the $\text{in vivo}$ analgesic activity of β-endorphin.